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Impact of vitamin A supplementation on infant
and childhood mortality
Aamer Imdad1, Mohammad Yawar Yakoob1, Christopher Sudfeld2, Batool A Haider1, Robert E Black2,
Zulfiqar A Bhutta1*
Abstract
Introduction: Vitamin A is important for the integrity and regeneration of respiratory and gastrointestinal epithelia
and is involved in regulating human immune function. It has been shown previously that vitamin A has a
preventive effect on all-cause and disease specific mortality in children under five. The purpose of this paper was
to get a point estimate of efficacy of vitamin A supplementation in reducing cause specific mortality by using
Child Health Epidemiology Reference Group (CHERG) guidelines.
Methods: A literature search was done on PubMed, Cochrane Library and WHO regional data bases using various
free and Mesh terms for vitamin A and mortality. Data were abstracted into standardized forms and quality of
studies was assessed according to standardized guidelines. Pooled estimates were generated for preventive effect
of vitamin A supplementation on all-cause and disease specific mortality of diarrhea, measles, pneumonia,
meningitis and sepsis. We did a subgroup analysis for vitamin A supplementation in neonates, infants 1-6 months
and children aged 6-59 months. In this paper we have focused on estimation of efficacy of vitamin A
supplementation in children 6-59 months of age. Results for neonatal vitamin A supplementation have been
presented, however no recommendations are made as more evidence on it would be available soon.
Results: There were 21 studies evaluating preventive effect of vitamin A supplementation in community settings which
reported all-cause mortality. Twelve of these also reported cause specific mortality for diarrhea and pneumonia and six
reported measles specific mortality. Combined results from six studies showed that neonatal vitamin A
supplementation reduced all-cause mortality by 12 % [Relative risk (RR) 0.88; 95 % confidence interval (CI) 0.79-0.98].
There was no effect of vitamin A supplementation in reducing all-cause mortality in infants 1-6 months of age [RR 1.05;
95 % CI 0.88-1.26]. Pooled results for preventive vitamin A supplementation showed that it reduced all-cause mortality
by 25% [RR 0.75; 95 % CI 0.64-0.88] in children 6-59 months of age. Vitamin A supplementation also reduced diarrhea
specific mortality by 30% [RR 0.70; 95 % CI 0.58-0.86] in children 6-59 months. This effect has been recommended for
inclusion in the Lives Saved Tool. Vitamin A supplementation had no effect on measles [RR 0.71, 95% CI: 0.43-1.16],
meningitis [RR 0.73, 95% CI: 0.22-2.48] and pneumonia [RR 0.94, 95% CI: 0.67-1.30] specific mortality.
Conclusion: Preventive vitamin A supplementation reduces all-cause and diarrhea specific mortality in children 6-
59 months of age in community settings in developing countries.
Introduction
Vitamin A includes a group of fat soluble compounds
that are involved in growth and differentiation of various
body cells. These include cells of the respiratory epithe-
lium, gastrointestinal tract, retina and immune system
[1]. Vitamin A has been termed as an anti-infectious
vitamin because of its role in regulating human immune
function. Early studies in animals and humans revealed
an association between vitamin A deficiency and
increased susceptibility to infections [1,2]. Its deficiency
makes humans, especially infants, vulnerable to diseases
of eye, respiratory and gastrointestinal tract [3]. These
observations encouraged evaluation of effect of vitamin
A supplementation on morbidity and mortality in ran-
domized controlled trials (RCTs).
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Past reviews have evaluated the impact of vitamin A
supplementation on infant and childhood mortality. A
meta-analysis combining 6 community-based RCTs
showed a reduction of 30% [Relative risk (RR) 0.70 95%
confidence interval (CI): 0.62-0.79] in all-cause mortality
and a reduction of 39% [RR 0.61 95% CI: 0.50-0.76] in
deaths from diarrheal disease in pre-school children [4].
There was no effect on deaths related to respiratory dis-
eases. Another systematic review including 10 RCTs
with 8 included in a meta-analysis, showed a significant
reduction of 23% [RR 0.77; 95% CI 0.68-0.88) in all-
cause mortality among vitamin A supplemented children
compared to controls in children 6-60 months of age
[5]. The review reported a significant reduction in mor-
tality due to diarrheal disease [RR 0.71; 95% CI: 0.57-
0.88) and measles [RR = 0.46; 95% CI: 0.22-0.98] and a
non-significant effect on deaths attributed to respiratory
disease [RR = 0.94; 95% CI: 0.63-1.42]. A review of vita-
min A supplementation in childhood and pregnancy
published in Lancet Under-nutrition Series by Gogia et
al. [6] also showed a significant reduction in all-cause
mortality in pre-school children [RR = 0.77, 95% CI:
0.63-0.95].
Reviews have also been conducted for neonatal vita-
min A supplementation. An analysis for neonatal vita-
min A supplementation by Haider et al. showed a
reduction of 20% [RR 0.80; 95 % CI: 0.66-0.96] in infant
mortality at 6 months of age; the results for mortality at
12 months of age were, however, not statistically signifi-
cant [RR 0.90; 95% CI: 0.61 to 1.32] [7]. Another meta-
analysis published in British Medical Journal evaluating
effect of neonatal vitamin A supplementation on infant
mortality showed that neonatal vitamin A supplementa-
tion had no effect in reducing all-cause mortality at 12
months of age [RR 0.92; 95% CI: 0.75 to 1.12] [8].
We evaluated all the available evidence on impact of
vitamin A supplementation in reducing infant and child-
hood mortality. This exercise is a part of series of efforts
to estimate efficacy of an intervention for input to Lives
Saved Tool (LiST) model [9]. An intervention is cur-
rently included in the LiST if there is evidence that it
reduces mortality among children less than five years of
age, either directly or indirectly. The process of generat-
ing a point estimate for efficacy of an intervention, in
reducing disease specific deaths or a risk factor, involve
qualitative evaluation of available evidence according to
Grading of Recommendations, Assessment, Develop-
ment and Evaluation (GRADE) criteria [10] and quanti-
tative measure according to Child Health Epidemiology
Reference Group (CHERG) rules [9]. For more details of
the review methods, the adapted GRADE approach or
the LiST model see the methods section and other arti-
cles in this supplement.
Methods
Searching
We systematically reviewed all published literature to
identify studies evaluating preventive effect of vitamin A
supplementation on infant and childhood mortality. We
searched PubMed, Cochrane Library, and all World
Health Organization Regional Databases and included
publications in any language. Following search strategy
was used on PubMed: [“Children” OR “Child” OR
“Infant” OR infan* OR “neonate” OR neonat* OR “new-
born” OR “Preschool”] AND [“vitamin A” OR “retinol”
OR “retino*”]. The search was limited to “clinical trial”
and “humans”. Last date of search was 3rd March 2010.
We scanned the titles and abstracts of the trials identi-
fied to exclude those that were obviously irrelevant,
retrieved the full text of the remaining trials, and identi-
fied relevant articles. We also reviewed the reference
lists of identified articles, existing reviews and meta-ana-
lyses and looked for studies that were not picked up in
the main search. Authors were contacted for any addi-
tional data, if required.
Inclusion/exclusion criteria
All the included studies were randomized or cluster
randomized controlled trials addressing vitamin A sup-
plementation in neonates (0-28 days of life) or children
< 5years of age. Trial authors were contacted if the
study population included some participants who were
not eligible for this review (e.g., children over 5 years),
and requested disaggregated data. If such data were
not available, studies were included if the majority of
participants met the inclusion criteria. If this could not
be determined and the participants met the inclusion
criteria on average, then these trials were included.
The comparison group in all the included studies was
either supplemented with a placebo or observed as
controls. In studies where vitamin A was supplemented
to both mother and infant we considered only those
pairs (of mother/infant) where mother received pla-
cebo or no intervention. Studies were included if they
reported data on: all-cause mortality and/or disease
specific mortality of diarrhea, pneumonia, measles,
meningitis and sepsis. The cause of death was assigned
as defined by the authors in individual studies, mostly
on the basis of verbal autopsies. Participants in all the
included studies were apparently healthy children in
whom prophylactic, synthetic vitamin A supplementa-
tion was initiated in neonatal period (<1 month of age)
or early childhood (1-59 months of age), We excluded
trials conducted on selected subgroups of infants, such
as those who were very low birth weight (<1500 g),
sick or admitted to hospital, as these have been exam-
ined elsewhere [11-14].
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Data abstraction
We abstracted the data of included studies onto a stan-
dardized abstraction form [9] for each outcome of inter-
est. We abstracted key variables with regard to the study
identifiers and context, study design and limitations,
intervention specifics, and outcome effects. The data
were entered by two authors and discrepancies were
removed if found.
Validity assessment
Each study was assessed and graded according to the
CHERG adaptation of the GRADE technique [9,10].
This method of assessment is based on scores allocated
to individual studies on the basis of study design, quality
of methods, relevance to the objectives of the review
and consistency across studies. Studies received an
initial score of high if a randomized or cluster rando-
mized trial and then the grade was decreased for each
study design limitation, if applicable. In addition, studies
reporting an intent-to-treat analysis or with statistically
significant strong levels of association (>80% reduction)
receive 1-2 grade increases. Each study was assigned a
quality grade of “high” “moderate” “low” or “very low”
on the basis of strengths and limitations of study. Any
study with a final grade of very low was excluded from
the analysis [9].
Quantitative data synthesis
We generated meta-analyses for impact of vitamin A
supplementation on all-cause and disease specific mor-
tality, where data was available from more than one
study. Relative risk was self calculated if not stated in
the study, with the following preference order for the
denominator: numbers with definite outcome known till
completion of intervention period, number randomized
and stated child years. For cluster randomized trials, we
used the stated cluster adjusted relative risk and 95%
confidence interval, irrespective of the method used. We
adjusted the results for cluster design if not stated in
the study. This was done by inflating the standard error
of calculated relative risk by square root of design effect
[15]. The value of design effect was taken as stated in
the study or was inferred from the previous review by
Beaton et al [5]. Pooled estimates of the evaluated out-
come measures were calculated by the generic inverse
variance method. This method is a common and simple
version of the meta-analysis procedure and is so named
because the weight given to each study is chosen to be
the inverse of the variance of the effect estimate (i.e.
one over the square of its standard error) [15]. In this
way larger studies, which have smaller standard errors,
are given more weight than smaller studies, which have
larger standard errors. This minimizes the imprecision
(uncertainty) of the pooled effect estimate. The
assessment of statistical heterogeneity among trials was
done by visual inspection i.e. the overlap of the confi-
dence intervals among the studies, and by the Chi
square (P-value) of heterogeneity in the meta-analyses
and I2 value. A low P value (less than 0.10) or a large
chi-squared statistic relative to its degree of freedom (I2
>50 %) was considered as providing evidence of signifi-
cant heterogeneity. In situations of substantial or high
heterogeneity being present, causes were explored by
sensitivity analysis and random effects model were pre-
ferred for pooled analysis. Although random model is
not a substitute for a thorough investigation of hetero-
geneity, it takes an ‘average’ effect from all the included
studies compared to fixed models that take the exact
contribution from the individual studies [15]. Results of
pooled estimates are described as relative risk (RR) with
95% confidence interval (95% CI). All meta-analyses
were conducted using software Review Manager version
5 [16].
We undertook a subgroup analysis for effect of vita-
min A supplementation in three age groups i.e. neo-
nates, infants 1-6 months and children 6-59 months of
age. This subgroup analysis was based on difference in
design and conduct of vitamin A supplementation in
neonates compared to older children [17] and going
beyond neonatal, on proposed differences in efficacy of
vitamin A in infants 1-6 months and children 6-59
months of age as reported previously [18]. We also
undertook subgroup analysis according to different geo-
graphical regions based on the hypothesis that preven-
tive vitamin A supplementation would have highest
impact on mortality in Asia. This premise was based on
the observation made in the latest report of WHO on
prevalence of vitamin A deficiency (serum retinol <0.70
μmol/l) worldwide [19]. According to this report South-
East Asia has the highest burden of biochemical vitamin
A deficiency. This subgroup analysis was however only
limited to all-cause mortality as we did not have suffi-
cient studies on cause specific mortality to conduct an
analysis according to various geographical regions.
We present our results of meta-analyses for all-cause
and cause specific mortality in the following theme:
pooled results from all the included studies irrespective
of age of supplementation, with sub-groups for supple-
mentation in neonates (0-28 days), infants 1-6 months
and children 6-59 months of age. To get a point esti-
mate of efficacy of preventive vitamin A supplementa-
tion, we summarized the evidence for each outcome
including qualitative assessment of ‘overall’ evidence
according to GRADE criteria and quantitative mea-
sures according to standard guidelines of CHERG
group [9]. The qualitative evaluation of the overall
(pooled) evidence was based on the volume and con-
sistency of the evidence across studies, the size of
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pooled relative risk and the strength of the statistical
evidence for an association between the intervention
and the health outcome as reflected in the p-value. In
this way, we generated estimated efficacy of vitamin A
supplementation in reducing disease specific mortality
for the developing countries in community settings
and gave our recommendations for input to Lives
Saved Tool (LiST) model [9].
Results
Trial flow
We identified 1251 titles from searches conducted in all
databases (Figure 1). After screening the titles and
abstracts, 40 studies were initially considered eligible
and finally, 21 studies were selected for final data
abstraction. We evaluated the impact of preventive vita-
min A supplementation on the following outcomes: all-
cause mortality, disease specific mortality of diarrhea,
pneumonia, measles, meningitis and sepsis.
Study characteristics
Additional File 1 presents characteristic of included stu-
dies. There were 21 randomized controlled trials that
addressed preventive vitamin A supplementation in infants
or children and reported all-cause mortality [20-40]. Of
these, 10 were individual RCTs [28,31-37,39,40], while 10
were cluster randomized trials [20-25,27,29,30,38]. The
paper by WHO VAST (Vitamin A Supplementation
Treatment) group [26] in Ghana was divided into two stu-
dies: VAST survival study (mainly looked at mortality out-
comes) and VAST health study (mainly looked at
morbidity outcomes). VAST health study was an indivi-
dual randomized controlled trial while VAST survival
study was cluster randomized. Participants in five studies
Studies reviewed with potential of 
eligibility         n= 40
Included studies 21 
            Titles screened    1251 
Exclusion of studies not meeting our 
eligibility criteria  
Excluded after screening of titles and abstracts 
All-cause 
mortality 
          n=21 
Diarrhea and 
pneumonia
specific 
mortality 
           n=12
Measles
specific
mortality 
          n= 6 
Meningitis 
specific
mortality 
n =8 
Sepsis
specific
mortality 
n =4 
Figure 1 Synthesis of study identification in review of the effects of vitamin A supplementation on infant and childhood mortality.
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were all neonates [31,35-38], while in nine they were aged
1-59 months [21,22,24,28,30,32,33,39,40]. Seven studies
also included children more than five years of age
[20,23,25-27,29,34]. Disaggregated data for children < 5
years of age was available from two of these studies and
was thus used accordingly [20,23]. For rest of the studies
we used the data according to the inclusion criteria. Vita-
min A was supplemented in synthetic form in a dose of
50,000 IU to neonates (0-28 days of life), 100,000 IU to
infants ( 1-12 months of age) and 200,000 IU to children
older than infants according to WHO guidelines [41]
except in three studies [21,33,39]. In one of these studies
[21], participants received a weekly dose of 8333 IU for 52
weeks, while in other two studies [33,39] it was a dose of
25 000 IU with immunization schedule. In three studies
comparison group did not receive a placebo but children
were simply observed as controls [20,24,39]. The coverage
of intervention was high and it reached > 90 % in fifteen
of the included studies [20-23,25-27,31-33,35-38,40]. All
the included studies were from developing countries.
Additional File 2 presents risk of bias table according to
the Cochrane handbook.
Quantitative data synthesis
All-cause mortality
Pooled results from all the 21 included studies showed
that prophylactic vitamin A supplementation reduced
all-cause mortality by 15% [RR 0.85, 95% CI: 0.76-0.94,
random model] in children 0-59 months of age (data
not shown). We did separate analyses for vitamin A
supplementation in neonates, infants 1-6 months and
children 6-59 months of age. Data for preventive effect
of neonatal vitamin A supplementation was analyzed in
two stages: one when infant mortality was measured at
6 months and then that at 12 months of age. Combined
results from six studies in neonatal period showed that
vitamin A supplementation reduced all-cause mortality
by 12% at six months of age [RR 0.88, 95% CI: 0.79-
0.98, fixed model]. The sub-group analysis with respect
to geographical region for this outcome is also shown
which showed that neonatal vitamin A supplementation
has a protective effect in Asia but not in Africa (Figure
2). The overall result was, however, not statistically sig-
nificant at 12 months of age [RR 0.90, 95% CI: 0.56-
1.46, random model] (data not shown). In children 1-6
months of age, vitamin A supplementation had no effect
on all-cause mortality [RR 1.05; 95 % CI 0.88-1.26, fixed
model] (Figure 3). Preventive vitamin A supplementa-
tion in children 6-59 months of age reduced all-cause
mortality by 25% [RR 0.75, 95% CI: 0.64-0.88, random
model], with geographical sub-group analysis shown
(Figure 4). This subgroup analysis indicated that preven-
tive vitamin A supplementation had a prominent effect
in reducing all-cause mortality in Asia but the results
Study or Subgroup
1.1.1 Asian studies
West 1995 a
Humphrey 1996
Rahmathullah 2003
Klemm 2008
Subtotal (95% CI)
Heterogeneity: Chi² = 4.23, df = 3 (P = 0.24); I² = 29%
Test for overall effect: Z = 3.03 (P = 0.002)
1.1.2 African studies
Benn 2008
Malaba 2005
Subtotal (95% CI)
Heterogeneity: Chi² = 0.01, df = 1 (P = 0.92); I² = 0%
Test for overall effect: Z = 0.91 (P = 0.36)
Total (95% CI)
Heterogeneity: Chi² = 8.94, df = 5 (P = 0.11); I² = 44%
Test for overall effect: Z = 2.31 (P = 0.02)
Test for subgroup differences: Chi² = 4.70, df = 1 (P = 0.03), I² = 78.7%
log[Risk Ratio]
0.0676
-0.9416
-0.2484
-0.1625
0.131
0.1044
SE
0.2464
0.4543
0.1089
0.0829
0.1948
0.167
Weight
5.3%
1.5%
26.9%
46.4%
80.1%
8.4%
11.4%
19.9%
100.0%
IV, Fixed, 95% CI
1.07 [0.66, 1.73]
0.39 [0.16, 0.95]
0.78 [0.63, 0.97]
0.85 [0.72, 1.00]
0.83 [0.73, 0.93]
1.14 [0.78, 1.67]
1.11 [0.80, 1.54]
1.12 [0.88, 1.44]
0.88 [0.79, 0.98]
Risk Ratio Risk Ratio
IV, Fixed, 95% CI
0.2 0.5 1 2 5
Favours experimental Favours control
a: Data for neonatal supplementation only.
Figure 2 Forest plot for preventive effect of vitamin A supplemenation on all-cause mortality at six months of age with subgroup
analysis according to geographical region: supplementation in neonatal period.
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for Africa and Latin America were not statistically sig-
nificant. Applying a test for subgroup difference, showed
no statistically significant difference among the groups
(p=0.16). In infants 1-6 months there was no effect in
any of the geographical regions. In group 6-59 months
of age, five studies included children > 5 years of age
and disaggregated data were not available. Excluding
these studies from the analysis gives an estimate of 0.72
(95 % CI 0.62-0.83) which is not statistically different
form the overall estimate (p=0.36).
Disease specific mortality
Twelve studies reported disease specific mortality of
diarrhea and pneumonia [21,23-26,29,31,34-37,40]. Four
of these studies included neonates only [31,35-37] and
seven included children 6-59 of age [21,23-26,29,34].
Only one study in age group 1-6 months reported cause
specific mortality [40]. Pooled results from these studies
showed that prophylactic vitamin A supplementation
reduces diarrhea specific mortality by 26% [RR 0.74,
95% CI: 0.58-0.93, random model] in children 0-59
months of age. This effect was also significant for sup-
plementation in children 6-59 months of age [RR 0.70,
95% CI: 0.58-0.86, fixed model] (Figure 5), but not on
mortality at 12 months for neonatal supplementation
[RR 0.97, 95% CI: 0.43-2.19, random model] (Figure 6).
One study from group 1-6 months reported a non-
b. West 1995; data for 1-5 months of age only excluding neonatal, *data for 1-6 months only, ¶ study conducted in three 
countries India, Peru and Ghana and included children < 9 months of age. We included it in group 1-6 months as most of the children belong to 
this group.
Study or Subgroup
2.16.1 Asian studies
Daulaire 1992*
Mahalanabis 1997
West 1995b
Subtotal (95% CI)
Heterogeneity: Chi² = 0.08, df = 2 (P = 0.96); I² = 0%
Test for overall effect: Z = 0.80 (P = 0.42)
2.16.2 African studies
Newton 2008
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
2.16.3 Multicenter studies
WHO 1998¶
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Total (95% CI)
Heterogeneity: Chi² = 2.53, df = 4 (P = 0.64); I² = 0%
Test for overall effect: Z = 0.53 (P = 0.60)
Test for subgroup differences: Chi² = 2.45, df = 2 (P = 0.29), I² = 18.4%
log[Risk Ratio]
-0.01
0.0582
0.1133
1.536
-0.0408
SE
0.4538
0.3632
0.1352
1.086
0.1397
Weight
4.1%
6.4%
45.9%
56.3%
0.7%
0.7%
43.0%
43.0%
100.0%
IV, Fixed, 95% CI
0.99 [0.41, 2.41]
1.06 [0.52, 2.16]
1.12 [0.86, 1.46]
1.10 [0.87, 1.40]
4.65 [0.55, 39.04]
4.65 [0.55, 39.04]
0.96 [0.73, 1.26]
0.96 [0.73, 1.26]
1.05 [0.88, 1.26]
Risk Ratio Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 3 Forest plot for preventive effect of vitamin A supplemenation on all-cause mortality with subgroup analysis for geographical
region: supplementation in children 1-6 months of age.
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significant reduction of 12 % in diarrhea specific mortal-
ity [RR 0.88; 95 % CI 0.28-2.81] [40]. Vitamin A supple-
mentation had no overall effect on disease specific
mortality of pneumonia [RR 1.05, 95% CI: 0.82-1.33,
fixed model] in children 0-59 months of age. A sub-
group analysis showed no effect for children 6-59
months [RR 0.94; 95 % CI 0.67-1.30, fixed model]
(Figure 7) and neonates [RR 1.17, 95 % CI: 0.82-1.68,
fixed model] (Figure 8). One study in group 1-6 months
also showed no effect [RR 1.33; 95 % CI 0.37-4.80] [40].
Disease specific mortality of measles was reported by
six studies [21,23,24,26,29,37]. From these studies only
one study addressed vitamin A supplementation in neo-
natal period [37]. Pooled results from these studies
showed that vitamin A supplementation reduced
measles specific mortality [RR 0.73, 95% CI: 0.47-1.13,
fixed model]; however, the results were not statistically
significant. Results were similar for children 6-59
months of age [RR 0.71, 95% CI: 0.43-1.16, fixed model]
(Figure 9) when mortality results of neonatal study [RR
0.8, 95% CI: 0.3-2.2] were excluded from the analysis.
No study reported measles specific mortality in infants
1-6 months of age.
We also looked for effect of vitamin A supplementa-
tion on sepsis and meningitis specific mortality. Com-
bined results from eight studies [26,29,31,34-37,40]
showed that prophylactic vitamin A supplementation
had no significant effect on meningitis specific mortality
[RR 0.76, 95% CI: 0.45-1.29, fixed model] in children 0-
59 months of age. A subgroup analysis for mortality at
12 months for supplementation in neonates [RR 0.79,
95% CI: 0.44-1.43, fixed model] (Figure 10) and for mor-
tality in children 6-59 months of age [RR 0.73, 95% CI:
0.22-2.48, fixed model] (Figure 11) had similar results. A
Study or Subgroup
2.15.1 Asian Studies
Sommer 1986¶
Vijayaraghavan 1990
West 1991#
Rahamatullah 1990
Daulaire 1992*
Agarwal1995
Venkatarao 1996
Chowdhury 2002
Subtotal (95% CI)
Heterogeneity: Tau² = 0.01; Chi² = 8.65, df = 7 (P = 0.28); I² = 19%
Test for overall effect: Z = 3.86 (P = 0.0001)
2.15.2 African Studies
Herrera 1992
VAST survival 1993
VAST health 1993
Subtotal (95% CI)
Heterogeneity: Tau² = 0.08; Chi² = 8.32, df = 2 (P = 0.02); I² = 76%
Test for overall effect: Z = 1.20 (P = 0.23)
2.15.3 Latin American studies
Stansfield 1993
Barreto 1994
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.04, df = 1 (P = 0.84); I² = 0%
Test for overall effect: Z = 0.87 (P = 0.39)
Total (95% CI)
Heterogeneity: Tau² = 0.03; Chi² = 20.47, df = 12 (P = 0.06); I² = 41%
Test for overall effect: Z = 3.52 (P = 0.0004)
log[Risk Ratio]
-0.2484
-0.0304
-0.3424
-0.7765
-0.3424
-0.1392
-1.1394
-1.966
0.0582
-0.2107
-1.203
-0.2107
-0.01
SE
0.144
0.3548
0.1144
0.3712
0.1595
0.5623
0.6571
0.7673
0.1309
0.0971
0.4531
0.2367
0.9979
Weight
13.8%
4.3%
16.4%
4.0%
12.6%
1.9%
1.4%
1.1%
55.6%
14.9%
18.0%
2.9%
35.8%
8.0%
0.7%
8.6%
100.0%
IV, Random, 95% CI
0.78 [0.59, 1.03]
0.97 [0.48, 1.94]
0.71 [0.57, 0.89]
0.46 [0.22, 0.95]
0.71 [0.52, 0.97]
0.87 [0.29, 2.62]
0.32 [0.09, 1.16]
0.14 [0.03, 0.63]
0.70 [0.58, 0.84]
1.06 [0.82, 1.37]
0.81 [0.67, 0.98]
0.30 [0.12, 0.73]
0.79 [0.54, 1.16]
0.81 [0.51, 1.29]
0.99 [0.14, 7.00]
0.82 [0.52, 1.29]
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1990
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Risk Ratio Risk Ratio
IV, Random, 95% CI
0.01 0.1 1 10 100
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Figure 4 Forest plot for preventive effect of vitamin A supplemenation on all-cause mortality with subgroup analysis for geographical
region: supplementation in children 6-59 months of age.
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study from group 1-6 months also showed no significant
effect [RR 0.35; 95 % CI 0.01-8.53] on meningitis speci-
fic mortality[40]. Four neonatal studies reported sepsis
specific mortality at 12 months [31,35-37] and the
pooled results showed that vitamin A supplementation
had no significant effect on sepsis specific mortality [RR
0.81, 95% CI: 0.52-1.26, fixed model] (Figure 12).
Recommendations for LiST model
We followed standardized guidelines to get estimates of
efficacy of vitamin A supplementation in reducing diar-
rhea, pneumonia, measles and meningitis specific mor-
tality, for input to LiST model [9]. In this paper we have
presented data for neonates, infants 1-6 months and
children 6-59 months of age; however, for the LiST tool,
we had focused on generating estimates for efficacy of
vitamin A supplementation in children 6-59 months of
age. No recommendations for neonatal vitamin A
supplementation are being made as neonatal vitamin A
supplementation is being evaluated as a separate inter-
vention [17] and randomized controlled trials are cur-
rently undergoing in Pakistan, India, Tanzania and
Malawi that will provide more evidence on the topic.
Also no recommendation is being made for infants 1-6
months because vitamin A supplementation has no
effect in this age group as shown previously [18] and in
this review.
Recommendations for LiST model are based on quali-
tative evaluation of pooled estimate and quantitative
inferences based in CHERG rules [9]. Additional File 3
summarizes the quality assessment and pooled estimates
for disease specific mortality. Vitamin A supplementa-
tion reduced diarrhea specific mortality by 30% [95% CI:
14% to 42%] in children 6-59 months of age. The quali-
tative assessment of the available evidence was that of
Study or Subgroup
Rahamathullah 1990
West1991
Herrara 1992
Daulaire 1992
VAST survival 1993
Agarwal1995
Chowdhury 2002
Total (95% CI)
Heterogeneity: Chi² = 5.77, df = 6 (P = 0.45); I² = 0%
Test for overall effect: Z = 3.48 (P = 0.0005)
log[Risk Ratio]
-0.7339
-0.4942
0.0099
-0.4307
-0.4155
-0.2484
-1.0788
SE
0.3775
0.2293
0.1984
0.2681
0.187
0.6769
0.8062
Weight
7.2%
19.5%
26.0%
14.2%
29.3%
2.2%
1.6%
100.0%
IV, Fixed, 95% CI
0.48 [0.23, 1.01]
0.61 [0.39, 0.96]
1.01 [0.68, 1.49]
0.65 [0.38, 1.10]
0.66 [0.46, 0.95]
0.78 [0.21, 2.94]
0.34 [0.07, 1.65]
0.70 [0.58, 0.86]
Risk Ratio Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 5 Forest plot for preventive effect of vitamin A supplementation on cause specific mortality of diarrhea: Supplementation in children 6-
59 months of age.
Study or Subgroup
Humphrey 1996
Rahmathullah 2003
Malaba 2005
Benn 2008
Total (95% CI)
Heterogeneity: Tau² = 0.43; Chi² = 8.58, df = 3 (P = 0.04); I² = 65%
Test for overall effect: Z = 0.08 (P = 0.93)
Weight
15.7%
31.7%
20.9%
31.7%
100.0%
IV, Random, 95% CI
0.40 [0.08, 2.03]
0.50 [0.25, 1.00]
2.37 [0.67, 8.34]
1.60 [0.80, 3.20]
0.97 [0.43, 2.19]
Risk Ratio Risk Ratio
IV, Random, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 6 Forest plot for preventive effect of vitamin A supplementation on cause specific mortality of diarrhea: Supplementation in neonatal
period.
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‘moderate” level. We recommended the above men-
tioned estimate for LiST model based on CHERG ‘rule
2’ which states that “If there is high- or moderate-qual-
ity evidence of effect on cause-specific mortality…Then
use the mortality effect”. The p-value for this estimate
was <0.0001, which shows the strength of statistical
association.
Pooled estimates for effect of vitamin A supplementa-
tion showed a non-significant reduction in pneumonia
[RR 0.94 95% CI: 0.67-1.30, p=0.70], measles [RR 0.71,
95% CI: 0.43-1.16, p=0.17] and meningitis [RR 0.73, 95%
CI: 0.22-2.48, p=0.62] specific mortality in children 6-59
months of age. The quality grade for all these estimates
was that of ‘low’ level. These estimates are not being
recommended for LiST model as results were not statis-
tically significant and p value for all the above estimates
was more than 0.10. According to CHERG method’s
paper a p value of < 0.10 is required for pooled estimate
to be considered for inclusion in the LiST tool [9].
Discussion
The impact of vitamin A supplementation on infant and
childhood mortality had been reviewed previously and it
has been established that vitamin A has a definite role
in reducing all-cause mortality in children older than six
months of age [4,5,7,18,42]. A recent trial conducted in
India, that is not yet published, showed that vitamin A
supplementation has no effect in prevention of mortality
in children aged 12-72 months [RR 0.96, 95 % CI: 0.89-
1.03] [43]. Although we did not include results of this
study in our analysis, as we required full text for
GRADE evaluation, combining its results with other
Study or Subgroup
Rahamathullah 1990
West1991
Herrera 1992
Daulaire 1992
VAST survival 1993
Agarwal1995
Chowdhury 2002
Total (95% CI)
Heterogeneity: Chi² = 6.52, df = 6 (P = 0.37); I² = 8%
Test for overall effect: Z = 0.39 (P = 0.70)
log[Risk Ratio]
-0.4155
0.2546
-0.843
-0.0512
0
0.6575
-1.966
SE
0.9758
0.2771
0.4554
0.6337
0.2785
2.3474
1.3461
Weight
3.0%
37.2%
13.8%
7.1%
36.8%
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1.6%
100.0%
IV, Fixed, 95% CI
0.66 [0.10, 4.47]
1.29 [0.75, 2.22]
0.43 [0.18, 1.05]
0.95 [0.27, 3.29]
1.00 [0.58, 1.73]
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0.14 [0.01, 1.96]
0.94 [0.67, 1.30]
Risk Ratio Risk Ratio
IV, Fixed, 95% CI
0.005 0.1 1 10 200
Favours experimental Favours control
Figure 7 Forest plot for preventive effect of vitamin A supplementation on cause specific mortality of pneumonia: Supplementation in children
6-59 months of age.
Study or Subgroup
Humphrey 1996
Rahmathullah 2003
Malaba 2005
Benn 2008
Total (95% CI)
Heterogeneity: Chi² = 0.64, df = 3 (P = 0.89); I² = 0%
Test for overall effect: Z = 0.85 (P = 0.39)
Weight
4.1%
41.6%
34.9%
19.4%
100.0%
IV, Fixed, 95% CI
0.66 [0.11, 3.96]
1.13 [0.64, 1.98]
1.35 [0.73, 2.49]
1.10 [0.48, 2.50]
1.17 [0.82, 1.68]
Risk Ratio Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 8 Forest plot for preventive effect of vitamin A supplementation on cause specific mortality pneumonia: Supplementation in neonatal
period.
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studies does not change the results significantly for all-
cause mortality in children 6-59 months of age [RR
0.78, 95 % CI: 0.68-0.91, random model].
Preventive vitamin A supplementation in children 6-
59 months of age showed a highly significant reduction
of 30% (95% CI: 14%-42%) in diarrhea specific mortality.
There was no heterogeneity in the pooled data (I2=0%).
The qualitative assessment of the available evidence
according to GRADE criteria was that of ‘moderate’
level. The estimated reduction also corresponds to
reduction in all-cause mortality in the same age group
(Figure 4) and diarrhea specific mortality reported in
other reviews [4,5]. This concludes that reduction of 30
% (95% CI: 14%-42%) is the best estimate of efficacy of
vitamin A supplementation in reducing diarrhea specific
mortality in children 6-59 months of age.
Despite the non-significant findings in our meta-analy-
sis, an effect of vitamin A supplementation on measles-
specific mortality is biologically plausible given the strong
beneficial effect of vitamin A for treatment of measles at
200,000 IU for 2 days [RR: 0.40 95% CI 0.19-0.87] [13].
Preventive effect of vitamin A supplementation for
measles related mortality may not be as apparent as
administration at the onset of disease; as the incidence of
disease has decreased at the first place due to large scale
measles vaccination and extremely large trials are
required to detect a statistically significant difference in
measles related mortality. Nevertheless, in the absence of
statistically significant data to support an effect, preven-
tive vitamin A supplementation cannot be linked with
measles mortality in this edition of the LiST model [9].
Impacts of preventive vitamin A supplementation on
Study or Subgroup
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West 1991
Daulaire 1992
VAST survival 1993
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log[Risk Ratio]
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-0.4004
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0.0392
SE
0.652
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1.591
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1.087
Weight
14.8%
8.1%
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5.3%
100.0%
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0.24 [0.04, 1.36]
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0.82 [0.45, 1.48]
1.04 [0.12, 8.76]
0.71 [0.43, 1.16]
Risk Ratio Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 9 Forest plot for preventive effect of vitamin A supplementation on cause specific mortality of measles: Supplementation in children 6-59
months of age.
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Total (95% CI)
Heterogeneity: Chi² = 2.68, df = 3 (P = 0.44); I² = 0%
Test for overall effect: Z = 0.79 (P = 0.43)
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Risk Ratio Risk Ratio
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0.01 0.1 1 10 100
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Figure 10 Forest plot for preventive effect of vitamin A supplementation on cause specific mortality of Meningitis: Supplementation in neonatal
period.
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other disease specific mortalities like that of meningitis
[RR 0.73, 95% CI: 0.22-2.48] and pneumonia [RR 0.94,
95% CI: 0.67-0.1.30] also showed a non-significant reduc-
tion in children 6-59 months of age. A review by WHO
pneumonia working group also showed that vitamin A
supplementation had no beneficial effect on pneumonia
related mortality in children more than six months of age
[18]. In the same review, data was pooled for all-cause
and pneumonia specific mortality in different age groups.
The overall results for all-cause mortality in children < 5
years was similar to ours [RR 0.77; 95 % CI 0.71-0.84].
Also there was no significant effect of vitamin A on all-
cause and pneumonia specific mortality in infants 0-5
months of age [RR0.97; 95 % CI 0.73-1.29 and 0.88; 95%
CI 0.51-1.51 respectively]. Our results for age group 1-6
months also showed no significant effect on all-cause
mortality [RR 1.05; 95 % CI 0.88-1.26]. These findings
may be attributed to the fact that about 75 % of pneumo-
nia related deaths in pre-school children occur in infants
and about 85 % of them occur in infants < 6 months of
age [18] and vitamin A has no effect in reducing pneu-
monia specific mortality as is shown in the above men-
tioned review [18].
Assessment of protective effect of neonatal vitamin A
supplementation on infant mortality has been inconsis-
tent. In a review published in Lancet Under-nutrition
Series [7] combining three neonatal vitamin A studies
showed a reduction of 20% [95% CI: 4% to 34%] in vita-
min A supplemented group compared to control at 6
months of age. The results, however, were not statisti-
cally significant at 12 months of age [0.90, 95 % CI:
0.61-1.32]. A review published in BMJ by Gogia et al [8]
combined data from six randomized controlled trials
also suggested that neonatal vitamin A supplementation
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0.01 0.1 1 10 100
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Figure 11 Forest plot for preventive effect of vitamin A supplementation on cause specific mortality of Meningitis: Supplementation in children
6-59 months of age.
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Figure 12 Forest plot for preventive effect of vitamin A supplementation on cause specific mortality of Sepsis: Supplementation in neonatal
period.
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has no protective effect on all-cause mortality at 12
months of age [RR 0.92, 95% CI: 0.75-1.12]. We were
able to get disintegrated data for all-cause mortality at
six months of age from all neonatal studies. Our results
showed that neonatal vitamin A supplementation
reduced infant mortality by 12% (95 CI: 2% to 21%] at 6
months of age. This implies that neonatal vitamin A
supplementation may have more prominent effect in
reducing early infant mortality (< 6 months of age) than
that at late infancy. As more evidence for efficacy of
neonatal vitamin A supplementation will be available
from various regions of the world, it may be appropriate
to wait for the results of large scale trials in Asia and
Africa before recommending this intervention for inclu-
sion in the LiST model.
It is interesting to note that preventive vitamin A
supplementation has a differential effect in reducing
all-cause mortality in Asia compared to Africa and
Latin America (Figures 2 and 4). However the sub-
group difference for children 6-59 was not statistically
significant (p=0.16). This differential effect has already
been described for neonatal vitamin A supplementa-
tion [44,45] but has not been noted previously for sup-
plementation in children 6-59 months of age. The
exact reasons for these differential effects are not
known however one explanation could be that accord-
ing to WHO [19], the highest proportions of pre-
school age children with biochemical vitamin A defi-
ciency (serum retinol <0.70 μmol/l), live in South-East
Asia (Figure 13). Africa on the other hand has the sec-
ond highest prevalence of biochemical vitamin A defi-
ciency. It is important to note that two of three
studies conducted in Africa in children 6-59 showed a
statistically significant effect in reducing all-cause
mortality. The confidence interval of pooled relative
risk for Africa was not far above unity. This showed
that there may be a protective effect in Africa but not
as prominent as that in Asia. In any case, there is not
sufficient evidence to decide in favor or against of a
true differential effect for vitamin A supplementation
in Asia vs. Africa and Latin America in children 6-59
months of age.
The dose of vitamin A supplementation in most of
the included studies was 200 000 IU every 4 or 6
months. It has been suggested previously that this regi-
men of vitamin A supplementation may just be mar-
ginally sufficient to keep adequate stores of vitamin A
in the body [5]. One of the included studies that used
Figure 13 Distribution of Biochemical vitamin A deficiency (retinol) as a public health problem by country 1995-200 in Preschool-age
children: (Taken from; Global prevalence of vitamin A deficiency in populations at risk 1995–2005. WHO Global Database on Vitamin A
Deficiency? Geneva, World Health Organization, 2009).
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weekly supplementation showed more prominent effect
in reducing all-cause mortality compared to other stu-
dies [21]. In any case the most important inference to
make is that it is the improvement of vitamin A status
rather than the method of improving it that makes it
the important determinant in reducing all-cause
mortality.
Vitamin A supplementation seems to be a relatively
safe intervention. Few children may suffer mild adverse
effects with the standard dosage of vitamin A supple-
mentation; however, they are rare and transient. The
most commonly reported side effects include irritabil-
ity, loose stools, headache, fever, nausea, vomiting and
bulging fontanel (in neonates) [46-48]. Although we
did not specifically pool results for different side
effects profiles; however, results from previous reviews
showed that there is no significant increased risk of
any adverse effect. In the review by Gogia et al, pooled
results from the included studies showed that vitamin
A supplementation in neonates did not significantly
increase risk of bulging fontanel, vomiting, irritability,
diarrhea, or fever [8].
Our review has several limitations. Three of the
included studies had comparison groups that received
no placebo [20,24,39]. This may bias the results through
the “Hawthorne effect”[49]. We were unable to identify
any significant predictor of substantial heterogeneity for
all-cause and disease specific mortalities. There may be
factors, not examined by us, that might explain the
observed differences. For example, effects of micronutri-
ent supplementation might be different between boys
and girls [42,50]. In the review by Gogia et al. pooled
results from four neonatal studies showed that the risk
of mortality was lower among boys [RR 0.77, 95 % CI:
0.59, 1.01) than girls (RR 0.93, 95 % CI: 0.73, 1.17) [8].
These divergent results for neonatal vitamin A supple-
mentation might be explained by differences in vaccina-
tion intensity as vitamin A supplementation has been
shown to interact negatively with DPT vaccination in
girls [37,51]. Other possible important factors contribut-
ing to heterogeneity may include feeding practices of
participants, dosage and number of vitamin A supple-
mentation, vaccination status, maternal vitamin A status
and HIV prevalence [12,45,52,53].
In conclusion, vitamin A supplementation has a defi-
nite role in reducing all-cause and diarrhea specific mor-
tality in children 6-59 months of age. Impacts for
measles and meningitis specific mortality, however,
showed no effect. There is also no role of vitamin A
supplementation for prevention of pneumonia specific
mortality. While there is a suggestion of benefit of neo-
natal vitamin A supplementation on mortality at 6
months of age, this observation must be verified in
other large scale studies in varied geographic regions
and await further information from the four large scale
trials which are underway.
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